Date: 2012-05-03
Type of information: Distribution agreement
Compound: Denarase (Serratia marcescens nuclease for biopharmaceutical applications)
Company: Sartorius Stedim (Germany) c-LEcta (Germany)
Therapeutic area:
Type agreement: distribution
Action mechanism: Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies.
Disease:
Details: Sartorius Stedim Biotech and c-LEcta, have announced the signing of a worldwide sales and distribution agreement for c-LEcta’s proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name “Denarase” through all regular Sartorius Stedim Biotech sales channels.
Financial terms:
Latest news:
